Is Small vs. Large Molecule Distinction Nonsensical?
Lots of angst between the FEDA and Pharma over drug pricing controls and price negotiations. There will be lobbying a’plenty by Pharma to mitigate what is already
June 22, 2023
Lots of angst between the FEDA and Pharma over drug pricing controls and price negotiations. There will be lobbying a’plenty by Pharma to mitigate what is already
The FDA recently approved a new extended release oral-suspension therapy, Lumryz (sodium oxybate) from Avadel Pharmaceuticals, for the treatment of cataplexy or excessive daytime sleepiness
And the beat goes on…….. We’ve covered the market moves of both CVS and Walgreens as they transition from a pharmacy centric business model to
The excitement in the air is palpable…. Yes, another biosimilar to Humira has been approved by the FDA!! Hallelujah!! Ummm….. wait….. the degree of excitement may be….. exaggerated.
A few weeks ago, we sent a Report asking whether value-based (VB) contracting had a heartbeat. Today we have evidence that a meaningful heartbeat has been
From time to time we run across an article that offers more than just recent industry news. Today we stumbled across an article that we suggest
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
The FDA recently approved a new subcutaneous therapy, Epkinly (epcoritamab-bysp) from Genmab, for the treatment of adult patients with relapsed or refractory (R/R) diffuse large
The FDA just approved a new rare, GENE therapy, Vyjuvek (beremagene geperpavec-svdt) from Krystal Biotech, indicated for the treatment of patients six months of age
A survey just released by the Pharmaceutical Strategies Group confirmed what we already know….. that the COST of specialty medications is the tipppty toppest key concern of
